Mahmoud M Khattab
Overview
Explore the profile of Mahmoud M Khattab including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joodi S, Ibrahim W, Khattab M
Inflammopharmacology
. 2025 Jan;
33(1):195-214.
PMID: 39752040
The currently approved drugs for Alzheimer's disease (AD) are only for symptomatic treatment in the early stages of the disease but they could not halt the neurodegeneration, additionally, the safety...
2.
B Abo-Zalam H, El Denshary E, A Abdalsalam R, Khalil I, Khattab M, Hamzawy M
Adv Pharm Bull
. 2024 Aug;
14(2):364-377.
PMID: 39206395
Purpose: The objective of this study was to develop a nanoencapsulated platform for coenzyme Q10 nanoparticles (coQNPs) or selenium nanoparticles (SeNPs) and explore their potential therapeutic benefits in treating hyperlipidemia...
3.
Mansour A, Khattab M, El-Khatib A, Awaad A, El-Refaie W, El-Mezayen N
Life Sci
. 2024 Aug;
353:122939.
PMID: 39094905
Aims: Transactivation of insulin-growth-factor-receptor (IGF-1R) by angiotensin-II-type-1-receptor (AT-1R) was only demonstrated in vascular-smooth-muscle cells and has never been tested in breast-cancer (BC). This investigation addressed the impact of chronic AT-1R...
4.
El-Khatib Y, Sayed R, Sallam N, Zaki H, Khattab M
Psychopharmacology (Berl)
. 2024 Jul;
242(1):233-234.
PMID: 39066868
No abstract available.
5.
Mansour H, Mohamed A, Khattab M, El-Khatib A
Brain Res
. 2024 Mar;
1834:148893.
PMID: 38554797
Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra. The dopamine D3 receptor (D3R) plays a significant role in the pathogenesis and treatment...
6.
Mansour H, Mohamed A, Khattab M, El-Khatib A
Eur J Pharmacol
. 2024 Feb;
966:176371.
PMID: 38302369
No abstract available.
7.
Mansour H, Mohamed A, Khattab M, El-Khatib A
Neuroscience
. 2023 Dec;
537:32-46.
PMID: 38040085
Parkinson's disease (PD) is the second most common neurodegenerative disease, characterized by abnormal α-synuclein misfolding and aggregation, mitochondrial dysfunction, oxidative stress, as well as progressive death of dopaminergic neurons in...
8.
Mansour H, Mohamed A, Khattab M, El-Khatib A
Food Chem Toxicol
. 2023 Oct;
181:114069.
PMID: 37820786
Parkinson's disease (PD) is characterized by motor impairments and progressive dopaminergic neuronal death in the substantia nigra (SN). Recently, the involvement of other regulated cell death (RCD) machineries has been...
9.
Mansour H, Mohamed A, Khattab M, El-Khatib A
Eur J Pharmacol
. 2023 Jun;
954:175875.
PMID: 37385578
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor deficits induced by dopaminergic neuronal death in the substantia nigra (SN). Finding a successful neuroprotective therapy is still challenging despite...
10.
Mansour H, Mohamed A, El-Khatib A, Khattab M
Ageing Res Rev
. 2023 Jan;
85:101841.
PMID: 36608709
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder in the world. Motor impairment seen in PD is associated with dopaminergic neurotoxicity in the striatum, and dopaminergic neuronal death...